Rituximab for people with multiple sclerosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rituximab for people with multiple sclerosis

Published:2021-02-16 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Filippini Graziella¹,Kruja Jera²,He Dian³,Del Giovane Cinzia⁴

Affiliation:

1. Scientific Director’s Office; Carlo Besta Foundation and Neurological Institute; Milan Italy

2. Neurology; UHC Mother Theresa; Tirana Albania

3. Department of Neurology; Affiliated Hospital of Guizhou Medical University; Guiyang China

4. Institute of Primary Health Care (BIHAM); University of Bern; Bern Switzerland

Publisher

Wiley

Subject

Pharmacology (medical)

Reference85 articles.

1. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients;Alping;Annals of neurology,2020

2. Banerjee S Adcock L Rituximab for the treatment of myasthenia gravis: a review of clinical effectiveness, cost-effectiveness, and guidelines www.ncbi.nlm.nih.gov/books/NBK537803/ 2018

3. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?;Bar-Or;Annals of Neurology,2010

4. The who, how and where of antigen presentation to B cells;Batista;Nature Reviews. Immunology,2009

5. Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues;Benedict;Lancet Neurology,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP